

## Ordinary General Meeting on April 26, 2019

**Paris (France), April 5, 2019 – 6 pm CET** – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today that Onxeo's shareholders are invited to attend the Company's Ordinary General Meeting which is being held on Friday, April 26, 2019 at 10.00 AM CET at Hotel Mercure Paris Vaugirard Porte de Versailles, 69 boulevard Victor, 75015 Paris, France. In the absence of a quorum, a new general meeting will be held on May 22, 2019 at 1 pm, in the same place.

The official notice of the General Meeting was published in the French Republic's *Bulletin des Annonces Légales Obligatoires* (i.e. the "Bulletin of Mandatory Legal Announcements") on March 22, 2019 and includes the agenda, the draft resolutions, and information on attendance and voting procedures. Under the conditions set out in current legislation, you can find the notice in its full length, together with all other related documents, on Onxeo's website: <http://www.onxeo.com/en/investisseurs/assemblee-generale/>

The above-mentioned documents are available to shareholders at the company's headquarters and on the Company's website. Shareholders may request to receive the documents by sending their request and postal or email address to Onxeo either by mail (Direction Financière – 49 boulevard du Général Martial Valin, 75015 Paris, France) or email ([investors@onxeo.com](mailto:investors@onxeo.com)).

### About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Onxeo is developing **AsiDNA™**, a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a unique decoy & agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the unique properties of AsiDNA™, notably its ability to oppose and even reverse tumor resistance to PARP inhibitors regardless of the genetic mutation status, and its strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The ongoing Phase I study DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) evaluates AsiDNA™ by systemic administration (IV) in solid tumors and has recently produced favorable tolerability and activity results.

AsiDNA™ is the first compound generated from **platON™**, the Company's proprietary chemistry platform of decoy oligonucleotides dedicated to generate new innovative compounds and broaden Onxeo's pipeline.

Onxeo's portfolio also includes **belinostat**, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2<sup>nd</sup> line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo's partner, Acrotech Biopharma L.L.C., under the name Beleodaq® (belinostat IV form).

**For further information, please visit [www.onxeo.com](http://www.onxeo.com).**

### Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.7.1.4 "Risk Factors" ("*Facteurs de Risque*") of the 2017 registration document filed with the *Autorité des marchés financiers* on April 25, 2018 under number D.18-0389, which is available on the *Autorité des marchés financiers* website ([www.amf-france.org](http://www.amf-france.org)) or on the Company's website ([www.onxeo.com](http://www.onxeo.com)).



## Contacts

### Onxeo

Valerie Leroy,  
Investor Relations  
[investors@onxeo.com](mailto:investors@onxeo.com)  
+33 1 45 58 76 00

### Media Relations

Nicolas Merigeau  
NewCap  
[onxeo@newcap.eu](mailto:onxeo@newcap.eu)  
+33 1 44 71 94 98

### Investor Relations / Strategic Communication

Dušan Orešanský / Emmanuel Huynh  
NewCap  
[onxeo@newcap.eu](mailto:onxeo@newcap.eu)  
+33 1 44 71 94 92

### Investor Relations US

Brian Ritchie  
LifeSci Advisors  
[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)  
+1 212 915 2578

PRESS RELEASE